Aurora Cannabis Inc - ACB STOCK NEWS

Aurora Cannabis Inc. (NASDAQ: ACB) (TSX: ACB) and Vectura Fertin Pharma, Inc. have launched the Luo CBD lozenge in Canada. This marks Vectura Fertin Pharma's first medical cannabis CBD product in the Canadian market. The lozenge, developed by Vectura Fertin Pharma, is manufactured by its subsidiary Cogent and distributed through Aurora's direct-to-patient e-commerce platform.

The collaboration aims to leverage Aurora's leading Canadian medical cannabis patient platform. The novel dissolvable format of the CBD lozenge offers easy dosing for patients. This launch follows the recent announcement of a commercial partnership between Cogent and Aurora, with plans to explore future medical cannabis product launches in Canada.

Aurora Cannabis Inc. (NASDAQ: ACB) (TSX: ACB) held its Annual General and Special Meeting on August 9, 2024, with 27.23% of issued and outstanding shares represented. All proposed matters were approved by shareholders, including the election of directors, appointment of Ernst & Young LLP as auditors, amendments to various compensation plans, renewal of the Shareholder Rights Plan, and a non-binding advisory resolution on executive compensation.

Notable voting results for director elections include Miguel Martin with 93.29% votes FOR, Chitwant Kohli with 92.37% votes FOR, and Norma Beauchamp with 89.47% votes FOR. The lowest approval was for Ron Funk, receiving 79.26% votes FOR.

Aurora Cannabis Inc. (NASDAQ: ACB) (TSX: ACB) announced its Q1 fiscal 2025 results, highlighting positive free cash flow of $6.5 million and a 12% year-over-year increase in total quarterly net revenue to $83.4 million. The company achieved record net revenue of $47.2 million in global medical cannabis and generated Adjusted EBITDA of $4.9 million, an 87% YoY increase. Aurora ended the quarter with a debt-free cannabis business and a cash position of ~$182 million. The company's performance was driven by strong growth in the global medical cannabis segment and a record contribution from its Bevo plant propagation business. Aurora's CEO, Miguel Martin, emphasized the company's commitment to operational excellence and strategic growth, positioning it well for sustained positive momentum.

Aurora Cannabis Inc. (NASDAQ: ACB) (TSX: ACB) and Vectura Fertin Pharma, Inc. have announced a commercial collaboration to launch a new CBD lozenge on Aurora's Canadian medical cannabis patient platform. The product, developed by Cogent International (a Vectura Fertin Pharma subsidiary), will be available to Aurora's patient base, providing valuable feedback and real-world data. This collaboration may lead to the potential commercialization of other Vectura Fertin Pharma medical cannabis products in Canada.

The initial agreement has a 24-month term, with the first CBD lozenge expected to launch later in 2024. Cogent will manufacture, package, and label the products for Aurora to distribute through its direct-to-patient e-commerce sales channel. This partnership aims to advance medical cannabis options in Canada while requiring minimal additional capital investment from Aurora.

Aurora Cannabis Inc. (NASDAQ: ACB) (TSX: ACB) is reminding shareholders to vote for its 2024 Annual General and Special Meeting, scheduled for August 9, 2024 at 1:00 p.m. Eastern Time. The proxy voting deadline is August 7, 2024 at 1:00 p.m. Eastern Time. The Board of Directors recommends voting FOR all director nominees and proposed resolutions.

Shareholders can attend the meeting via live webcast and are encouraged to review meeting materials available on Aurora's website and SEDAR+. For voting assistance, shareholders can contact Laurel Hill Advisory Group, Aurora's proxy solicitation agent. The company emphasizes that every vote is important, regardless of the number of shares owned.

Aurora Cannabis Inc. (NASDAQ: ACB) (TSX: ACB), a leading Canada-based global medical cannabis company, has announced its upcoming first quarter 2025 investor conference call. The call is scheduled for Wednesday, August 7, 2024, at 8:00 a.m. Eastern Time (6:00 a.m. Mountain Time). Aurora will release its financial results for Q1 2025 before the markets open on the same day.

The conference call will be hosted by CEO Miguel Martin and CFO Simona King, who will present the results and conduct a question and answer session. Investors can access the webcast through the company's website under the 'Investor Info' section.

Aurora Cannabis Inc. (NASDAQ: ACB) (TSX: ACB) has been granted expanded cultivation and unique research licenses by Germany's Federal Institute for Drugs and Medical Devices (BfArM) under the new Medical Cannabis Act. The licenses allow Aurora to continue domestic cultivation, add an approved additional product, and conduct R&D on up to seven novel cultivars at its EU GMP facility in Leuna. This expansion builds on Aurora's two-year history of cultivating approximately 1,000 kg of medical cannabis flower annually in Germany. The company views these licenses as recognition of its leadership in the region and commitment to high-quality cannabis production. Aurora anticipates that Germany's regulatory reforms will have a broader effect on the acceptance of medical cannabis across Europe.

Aurora Cannabis announces the availability of its management information circular for its upcoming annual general and special meeting of shareholders. The meeting will be held virtually on August 9, 2024, at 1:00 p.m. (Eastern time) / 11:00 a.m. (Mountain Time). Shareholders can access the circular on the company's website and SEDAR+. At the meeting, shareholders will vote on critical issues, including director nominees and meeting resolutions. Aurora emphasizes its recent financial stability and aims for positive free cash flow by the end of 2024. The company encourages shareholders to vote by August 7, 2024, and reach out to Laurel Hill Advisory Group for assistance.

Aurora Cannabis (NASDAQ: ACB) announced its FY2024 results, highlighting a record annual adjusted EBITDA of $12.8 million and a 21% increase in total net revenue compared to the previous fiscal year. In Q4 2024, the company achieved its sixth consecutive quarter of positive adjusted EBITDA, with total net revenue up 5% YoY to $67.4 million, driven by a 20% YoY growth in global medical cannabis revenue to $45.6 million. Aurora finished the fiscal year with approximately $180 million in cash and no cannabis-related debt. The company reaffirms its goal of achieving positive free cash flow by the end of 2024.